The startup develops precision diagnostics technology that enhances benchtop scale sequencers for liquid biopsies, enabling efficient detection of oncology and infectious diseases. By removing barriers to global access, the company increases the availability of molecular diagnostic tests for healthcare professionals.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for DNA sequencing library preparation can be complex, costly, and platform-dependent, limiting their accessibility and efficiency for various applications. Existing approaches may also introduce biases during amplification, compromising data accuracy and uniformity.
Solution
Genomill offers Geno1® technologies, including Bridge Capture™ and Nicking Loop™, that leverage circular DNA to simplify and enhance next-generation sequencing (NGS) workflows. Bridge Capture™ enables cost-efficient and sensitive targeted sequencing for genetics and diagnostics, while Nicking Loop™ facilitates platform-agnostic sequencing with improved uniformity and reduced amplification bias. These technologies transform DNA libraries into dynamic units, supporting database-like operations directly on DNA and making DNA data more accessible and interactive. By using circular DNA, Genomill's solutions provide a unified foundation for sequencing and diagnostics, improving data quality and streamlining workflows on established and emerging sequencing platforms.
Target Audience
Genomill's technologies target researchers, clinical laboratories, and diagnostic companies seeking to improve the efficiency, accuracy, and accessibility of DNA sequencing for applications in oncology, genetics, and beyond.
Features
- Bridge Capture™ for high-precision, cost-efficient targeted sequencing in genetics and diagnostics
- Nicking Loop™ for platform-agnostic sequencing, enabling direct use of circular libraries or conversion to linear libraries
- Compatibility with various NGS platforms, including Illumina, Ion Torrent, and Nanopore
- Simple and rapid workflows with minimal sample processing and hands-on time
- Cost-efficient testing using off-the-shelf reagents and standard laboratory infrastructure
- High sensitivity for challenging oncological applications, including detection of SNVs, indels, and gene fusions
- Ability to pool samples directly after the targeting step without quantification, enhancing scalability
- Potential for automation using platforms like Opentrons OT-2